Botox vs Xeomin: Which Neuromodulator to Stock and Offer Your Patients

Botox's accessory proteins may slow diffusion across the neuromuscular junction, which some clinicians argue provides a tighter, more predictable zone of effect. Xeomin's protein-free formulation theoretically allows faster onset and potentially broader diffusion, though clinical data on diffusion differences remain mixed. The practical implication: Xeomin users often report seeing results in 2–3 days versus Botox's typical 3–5 days, though full effect for both arrives around day 7–10. This matters when patients want rapid results before an event.

Dosing and Unit Economics

Here is where the math gets real. Xeomin requires approximately 1.2 to 1.3 times the units of Botox to achieve equivalent clinical effect—a phenomenon attributed to the absence of the protein complex. If you're treating a glabellar region with 20 units of Botox, you'll typically use 24–26 units of Xeomin.

On a per-unit basis, Xeomin has historically been priced lower than Botox, but the higher unit requirement can offset that advantage. Current wholesale pricing (verify with your supplier and loyalty program) typically ranges:

• Botox: $10–13 per unit (depending on volume tier and rebate structure via Alle or Aspire)
• Xeomin: $8–11 per unit (Evolus Rewards program pricing varies)

A 20-unit Botox treatment costs roughly $200–260; the equivalent Xeomin dose (24–26 units) runs $192–286. The gap narrows when you factor in rebate tiers. If you're moving high volume, Botox's Alle rebate program can push per-unit cost below $10; Evolus's Rewards program offers similar incentives but requires hitting different thresholds.

Onset and Patient Expectations

Xeomin's faster onset (48–72 hours vs. 72–96 hours for Botox) is clinically real but modest. For routine cosmetic patients, the difference is negligible. For event-driven cases—a wedding in 5 days—Xeomin edges ahead. Set expectations clearly either way; neither product is "instant."

Antibody Formation and Resistance

Both products carry a small risk of antibody formation against the toxin, rendering future treatments less effective. The naked formulation of Xeomin was originally thought to reduce immunogenicity, but long-term clinical data suggest the risk is similar. If a patient develops resistance (rare, <1% of users), switching between BoNT-A products (Botox, Xeomin, Daxxify) may restore response, though this is not guaranteed.

Patient Fit and Clinical Scenarios

Offer Botox if: you're treating high-volume patients seeking predictable, tight results; your patient base values the longest track record (Botox has 20+ years of cosmetic use); you're optimizing for rebate economics at scale.

Offer Xeomin if: patients specifically request faster onset; you're building a differentiated clinical brand around "naked toxin" messaging; you want flexibility in your toxin portfolio; your acquisition cost is meaningfully lower through your group purchasing or MSO structure.

Practical Recommendation

Most successful practices stock both. Botox remains the volume driver and the default for most patients—it's what they've heard of, what their friends use, and what carries the deepest clinical literature. Xeomin serves as a premium option for onset-sensitive patients and as a backup for those who may have developed antibodies to Botox. The dosing adjustment (1.2–1.3× multiplier) is straightforward to train staff on, and the clinical outcomes are equivalent at proper dosing.

Your choice ultimately hinges on your cost structure, patient demographics, and whether you're pursuing a multi-product strategy. If you're an MSO or group practice, negotiate both into your GPO agreement; the competitive pressure between AbbVie (Botox) and Evolus (Xeomin) works in your favor.